Patents Assigned to Cetus Corporation
-
Patent number: 5792458Abstract: A potent and specific immunotoxin is prepared by coupling an inactivated diphtheria toxin to a binding moiety such as a monoclonal antibody or transferrin. The immunotoxins are specific for human tumors and leukemias and are indistinguishable in cell toxicity from that of the native toxin linked to the binding domain without the toxicity to other cells. The immunotoxin is useful in treating graft versus host disease as well as selectively killing tumor cells, such as medulloblastoma and glioblastoma cells.Type: GrantFiled: October 17, 1994Date of Patent: August 11, 1998Assignees: The United States of America as represented by the Department of Health and Human Services, Cetus CorporationInventors: Virginia G. Johnson, Larry Greenfield, Richard J. Youle, Walter Laird
-
Patent number: 5702699Abstract: An improved process for recovering and purifying lipophilic recombinant proteins such as human .beta.-interferon from their hosts involves concentrating the bacteria; disrupting the cell wall and solubilizing the protein into an aqueous medium with an appropriate solubilizing agent; extracting the protein from the aqueous medium with 2-butanol, 2-methyl-2-butanol or mixtures thereof; precipitating and isolating the protein from the alcohol phase; purifying the protein by chromatography and diafiltering the protein against distilled water or aqueous solutions of ethanol or glycerol at a pH of about 12. Therapeutic formulations of such purified proteins with stabilizers contain SDS levels reduced to less than 10 p.p.m.Type: GrantFiled: June 7, 1995Date of Patent: December 30, 1997Assignee: Cetus CorporationInventors: Wolfgang H. Hanisch, Peter Fernandes
-
Patent number: 5643566Abstract: Highly stable, pharmaceutical compositions comprising a therapeutically effective amount of a biologically active recombinant lipophilic protein such as human .beta.-interferon and interleukin-2 dissolved in a non-toxic, inert, therapeutically compatible aqueous-based carrier at pH ranges of from about 6.8 to 7.8 and about 8.5 to 10, which formulations contain a stabilizer for the protein selected from the group comprising human serum album, human serum albumin and dextrose or human plasma protein fraction, and at a pH range of from about 2 to 4, which latter formulations optionally contain a carbohydrate and/or protein stabilizer, are disclosed. Further, preferred formulation processes to prepare said compositions are described which avoid highly alkaline conditions.Type: GrantFiled: June 7, 1995Date of Patent: July 1, 1997Assignee: Cetus CorporationInventors: Wolfgang H. Hanisch, Pete M. Fernandes, Terrance Taforo, James W. Thomson
-
Patent number: 5620849Abstract: Compositions and methods for identifying inhibitors of papilloma virus replication are described consisting of soluble cellular extracts supplemented with purified viral E1 and E2 proteins.Type: GrantFiled: September 23, 1994Date of Patent: April 15, 1997Assignees: Cetus Corporation, The Regents of the University of CaliforniaInventors: Michael R. Botchan, Liu Yang, Rong Li, Ian J. Mohr, Robin Clark
-
Patent number: 5372943Abstract: Lipid microemulsions which can be added to cell culture media to provide essential lipids in a bioavailable form and their components are disclosed. Methods to disperse lipids in culture media by the use of one or more emulsifiers are described. Further disclosed are media which support growth of cells and production of recombinant, viral and/or native products wherein lipids are supplied in the form of microemulsion.Type: GrantFiled: July 12, 1993Date of Patent: December 13, 1994Assignee: Cetus CorporationInventors: Duane Inlow, Brian Maiorella
-
Patent number: 5269937Abstract: A high angle light scattering detector using classical Rayleigh scattering. A high intensity arc light source, filtered to leave only one wavelength illuminates a flow cell. Through the flow cell, very small particles such as biological proteins flow in solution after separation by HPLC or some other means. A UV detector generates data regarding the weight concentration of the eluting particles and a scattered light detector collecting scattered light at angles of approximately 90.degree. generates a scattered light signal. The incident light intensity is also measured. The average molecular weight is then computed using the scattered and incident light data the weight concentration data and a simplified mathematical relationship from which the size factor P and the viral coefficients have been eliminated.Type: GrantFiled: October 23, 1990Date of Patent: December 14, 1993Assignee: Cetus CorporationInventors: Gavin D. Dollinger, Robert L. Cunico, Michael G. Kunitani
-
Patent number: 5268274Abstract: Nucleic acid sequences encoding the bacterial cellulose synthase operon derived from Acetobacter are disclosed. Methods for isolating the genes, vectors containing the genes, and transformed hosts useful for the expression of recombinant bacterial cellulose synthase or production of cellulose are also described.Type: GrantFiled: April 22, 1991Date of Patent: December 7, 1993Assignee: Cetus CorporationInventors: Arie Ben-Bassat, Roger D. Calhoon, Anna L. Fear, David H. Gelfand, James H. Meade, Rony Tal, Hing Wong, Moshe Benziman
-
Patent number: 5252603Abstract: Succinylacetone derived or related medicaments and methods of synthesis of the same are shown wherein the medicaments consists of succinylacetonyl-proline-PEG, succinylacetonyl-NH-PEG, or compounds that have the formula: ##STR1## wherein n=1-6R=CH.sub.3, CF.sub.3, --CO.sub.2 R.sup.IV, ##STR2## R.sup.I, R.sup.II =H, F, CH.sub.3, or ##STR3## R.sup.III =H, ##STR4## or tetrazolyl R.sup.IV =H, or alkyland that have immunosuppressive activity both in vivo and in vitro based on their activities in cellular immunologic assays and adjuvant induced arthritis in rats, respectively.Type: GrantFiled: December 6, 1990Date of Patent: October 12, 1993Assignee: Cetus CorporationInventors: Danute E. Nitecki, Lois Aldwin, Corey H. Levenson, Margaret Moreland, Irwin Braude, David F. Mark, Henry Rapoport
-
Patent number: 5250186Abstract: A high angle light scattering detector using classical Rayleigh scattering. A high intensity arc light source, filtered to leave only one wavelength illuminates a flow cell. Through the flow cell, very small particles such as biological proteins flow in solution after separation by HPLC or some other means. A UV detector generates data regarding the weight concentration of the eluting particles and a scattered light detector collecting scattered light at angles of approximately 90.degree. generates a scattered light signal. The incident light intensity is also measured. The average molecular weight is then computed using the scattered and incident light data, the weight concentration data and a simplified mathematical relationship from which the size factor P and the viral coefficients have been eliminated.Type: GrantFiled: October 9, 1992Date of Patent: October 5, 1993Assignee: Cetus CorporationInventors: Gavin D. Dollinger, Robert L. Cunico, Michael G. Kunitani
-
Patent number: 5220004Abstract: Methods and reagents for determining an individual's genotype at the .sup.G .gamma.-globin locus with respect to a set of three alleles using sequence-specific oligonucleotide probes enable one to type samples from a variety of sources, including samples comprising RNA or cDNA templates, and can be applied to nucleic acids in which a target region spanning the polymorphism has first been amplified. This three-allele system facilitates typing tissue for determining individual identity and has application in the field of forensic science.Type: GrantFiled: May 7, 1991Date of Patent: June 15, 1993Assignee: Cetus CorporationInventors: Randall K. Saiki, Shanavaz L. Nasarabadi
-
Patent number: 5216005Abstract: Succinylacetone derived or related medicaments and methods of synthesis of the same are shown wherein the medicaments consists of succinylacetonyl-proline-PEG, succinylacetonyl-NH-PEG, or compounds that have the formula: ##STR1## and that have immunosuppressive activity both in vivo and in vitro based on their activities in cellular immunologic assays and adjuvant induced arthritis in rats, respectively.Type: GrantFiled: December 6, 1990Date of Patent: June 1, 1993Assignee: Cetus CorporationInventors: Danute E. Nitecki, Lois Aldwin, Corey H. Levenson, Margaret Moreland, Irwin Braude, David F. Mark, Henry Rapoport
-
Patent number: 5208021Abstract: A potent and specific immunotoxin is prepared by coupling an inactivated diphteria toxin to a binding moiety such as a monoclonal antibody or transferrin. The immunotoxins are specific for human tumors and leukemias and are indistinguishable in cell toxicity from that of the native toxin linked to the binding domain without the toxicity to other cells. The immunotoxin is useful in treating graft versus host disease as well as selectively killing tumor cells, such as medulloblastoma and glioblastoma cells.Type: GrantFiled: January 25, 1989Date of Patent: May 4, 1993Assignees: The United States of America as represented by the Secretary of the Department of Health and Human Services, Cetus CorporationInventors: Virginia G. Johnson, Larry Greenfield, Richard J. Youle, Walter Laird
-
Patent number: 5173482Abstract: Succinylacetone derived or related medicaments and methods of synthesis of the same are shown wherein the medicaments consists of succinylacetonyl-proline-PEG, succinylacetonyl-NH-PEG, or compounds that have the formula: ##STR1## and that have immunosuppressive activity both in vivo and in vitro based on their activities in cellular immunologic assays and adjuvant induced arthritis in rats, respectively.Type: GrantFiled: December 6, 1990Date of Patent: December 22, 1992Assignee: Cetus CorporationInventors: Danute E. Nitecki, Margaret Moreland, Lois Aldwin, Corey H. Levenson, Irwin Braude, David F. Mark, Henry Rapoport
-
Patent number: 5166133Abstract: Proteins are described that affect adhesion of white blood cells (WBCs) to endothelial cells (ECs). The proteins include inter-.alpha.-trypsin inhibitor, .alpha..sub.1 -M, and HI-30. When administered in therapeutically effective amounts, these proteins can alter adhesion between WBCs and ECs to ultimately prevent inflammatory-type diseases.Type: GrantFiled: May 14, 1991Date of Patent: November 24, 1992Assignee: Cetus CorporationInventors: L. L. Houston, David Y. Liu, Zehra Kaymakcalan
-
Patent number: 5162507Abstract: A process for recovering highly pure, recombinant IL-2 from transformed microorganisms in which the cells are disrupted; impure recombinant IL-2 is isolated in the form of refractile bodies from the disruptate; the impure IL-2 is dissolved and denatured with at least 6M guanidine hydrochloride containing a reducing agent; the reduced IL-2 is precipitated and resolubilized; the reduced solubilized IL-2 therein is oxidized by a controlled oxidation; the oxidized IL-2 is refolded by reducing the concentration of guanidine hydrochloride in the solution; and the oxidized, refolded IL-2 is further purified by ion exchange chromatography or hydrophobic interaction chromatography and ion exchange chromatography.Type: GrantFiled: September 12, 1989Date of Patent: November 10, 1992Assignee: Cetus CorporationInventors: Sidney N. Wolfe, Glenn J. Dorin, John T. Davis, Flint Smith, Amy Lim, Robert Weissburg
-
Patent number: 5156964Abstract: This invention is in the field of cell and/or tissue culture. In particular, this invention relates to methods which adapt cells to a desired phenotype by exposing the cells to high levels of ammonia in culture, and subsequently transferring the adapted cells to a new culture medium in which there is no initial level of ammonia or the initial level of ammonia is below the level to which cells have been exposed to during the adaptation process. In this new culture medium, the adapted cells express the desired phenotype of growing to a higher viable cell density, and/or remaining viable for a longer period of time, and/or producing more of a desired cell product than their non-adapted counterparts grown in the same medium. This invention includes the adapted cells produced thereby and their cell products.Type: GrantFiled: January 21, 1992Date of Patent: October 20, 1992Assignee: Cetus CorporationInventors: Duane Inlow, Brian Maiorella, Andrea E. Shauger
-
Patent number: 5153265Abstract: A biologically active CSF-1 protein is selectively conjugated via certain amino acid residues or carbohydrate moieties to a water-soluble polymer selected from polyethylene glycol or polypropylene glycol homopolymers, polyoxyethylated polyols, or polyvinyl alcohol. The resulting conjugated CSF-1 is biologically active and has increased circulating half-life in mammals, compared to that of the unconjugated protein. The conjugated CSF-1 may be used to stimulate the immune response or to provide more cells to be stimulated.Type: GrantFiled: August 30, 1990Date of Patent: October 6, 1992Assignee: Cetus CorporationInventors: Paula J. Shadle, Kirston E. Koths, Margaret Moreland, Nandini Katre, Walter J. Laird, Lois Aldwin, Danute E. Nitecki, John D. Young
-
Patent number: 5149688Abstract: This invention is in the area of immunology, and specifically relates to immunopharmacology as applied to the development of immunosuppressive compositions and methods of use thereof for treating a wide variety of diseases arising from abnormal or undesirable normal immune responses. Compositions and methods of using the same that are particularly useful in treating autoimmune diseases are shown.Type: GrantFiled: April 24, 1990Date of Patent: September 22, 1992Assignee: Cetus CorporationInventors: Dale G. Ando, Corey H. Levenson, Irwin Braude
-
Patent number: 5137721Abstract: A vaccine is described for prevention of gastro-enteric disease caused in a mammalian species by a pathogenic microorganism. The vaccine comprises a non-pathogenic microorganism strain containing stable replicative plasmids, each having one or more genes non-indigenous to the plasmid. The non-indigenous genes are either genes for an adhesin necessary for adherence of the pathogenic microorganism in the mammalian species or are genes for toxoids of toxins causative of the disease. Both types of genes may also be included in the same plasmid.Type: GrantFiled: February 6, 1989Date of Patent: August 11, 1992Assignee: Cetus CorporationInventor: Walter S. Dallas
-
Patent number: H1198Abstract: Serotype-specific human anti-Pseudomonas monoclonal antibodies which bind to determinants of the cell wall lipopolysaccharides of P. aeruginosa are prepared from hybrid cell lines. The antibodies may be of any isotype. These antibodies may be used to treat infections caused by P. aeruginosa.Type: GrantFiled: April 26, 1985Date of Patent: June 1, 1993Assignee: Cetus CorporationInventors: James W. Larrick, Andrew A. Raubitschek